Recursion’s Post

Recursion announces that scientific and regulatory expert Namandje Bumpus, Ph.D. and biotech financial leader Elaine Sun, MBA have been appointed to Recursion’s Board of Directors, effective as of March 15th. 🔹 Dr. Bumpus served as the FDA’s Principal Deputy Commissioner and played a pivotal role in shaping the agency’s strategic direction and driving its day-to-day operations. She worked closely with the FDA Commissioner to spearhead key public health initiatives, strengthening regulatory frameworks, modernizing enterprise systems, and enhancing laboratory testing capabilities. She was also one of the foremost drivers of strategy for integration of AI into regulatory science at the agency. Prior to the FDA, Dr. Bumpus was an endowed professor and chair of the Department of Pharmacology and Molecular Sciences at The Johns Hopkins University School of Medicine, where she also served as an associate dean. She has won numerous awards, including the Presidential Early Career Award, the John J. Abel Award, and the Leon I. Goldberg Award. 🔹 Ms. Sun is a 30-year life sciences and financial industry veteran with a track record of building and creating value for early- to late-stage biopharmaceutical companies. She is currently the Chief Operating Officer and Chief Financial Officer at Mammoth Biosciences, an in vivo gene editing therapeutics company co-founded by Nobel laureate and CRISPR pioneer Jennifer Doudna. Her previous roles include SVP and CFO at Halozyme Therapeutics and CFO and Chief Strategy Officer at SutroVax (now Vaxcyte). Earlier in her career, she advised pharmaceutical, biotechnology and medical device companies on M&A and financing transactions valued in excess of $50 billion, including as Managing Director at Evercore Partners and Merrill Lynch. She currently serves on the Board of Dynavax Technologies (NASDAQ:DVAX) and Asher Biotherapeutics. “I am delighted to welcome Elaine and Namandjé to Recursion’s Board,” said Recursion Co-founder and CEO Chris Gibson, Ph.D. “As the company continues to grow its clinical pipeline and enhance its platform, our new board members’ scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success.” 👉 Read more: https://lnkd.in/eRunYDf7